

Difficulties in conducting an epidemiological study for endocrine disrupting chemicals

Seiichiro Yamamoto, Ph.D
Statistics and Cancer Control Division,
Research Center for Cancer Prevention and
Screening, National Cancer Center, Japan

The 8th International Symposium on Endocrine Disruption
in Okinawa, December 4-6

Evidence level of epidemiologic studies

Evidence Level	Study Design	Data collection	Unit	# subjects	Period	Cost
High	Randomized Controlled Trial	Pro-spective	Individual	1,000-100,000	10y rs	>\$10 mil
	Cohort study/Nested case-control study	Pro-spective	Individual	10,000-1,000,000	10y rs	\$10 mil
	Case-control study	Retro-spective	Individual	100-1000	2-3y rs	\$1 mil
	Cross-sectional study	Cross sectional	Individual	100-1000	1yr	<\$0.1 m
	Ecological study	Cross sectional	Population	<100 pops	0	0
Low	Time series	Cross sectional	Population	One population	0	0
	Expert opinion	-	-	-	-	-

Quality of evidence depends on the *accuracy of exposure measurements*

- Questionnaire vs. Biological marker
 - Quantitative vs. qualitative
 - Category vs. Dose response
 - Questionnaire does not take into account
 - Inter-individual variation in metabolism
 - many exposure pathway
- Measurement error in exposure assessment
 - Validity of EDC in serum/adipose tissue
 - Confounded by endogenous and other exogenous estrogen exposure

Quality of evidence also depends on the *study design*

- Prospective vs. retrospective
 - Selection bias
- Interventional vs. observational
 - Confounder assessment
- Number of high quality studies
 - Consistency of the results

I would rather emphasize the
difficulties in conducting epi studies

Summary of EDC epi studies

Report from MHLW WG for health effects of EDC

- Epidemiological study Searched by PubMed
 - Disease AND human AND
 - (insecticides OR pesticides OR chlorinated hydrocarbons OR pesticides OR chlorinated hydrocarbons OR pcbs OR bisphenol OR phenol OR phthalate OR styrene OR furan OR organotin OR diethylstilbestrol OR ethinyl estradiol)
 - Until 2004.10.31
- Diseases
 - Cancer
 - Breast, endometrium, ovary, prostate, testis, thyroid
 - Other diseases
 - Thyroid, hypospadias, cryptorchidism, child development, sperm count, allergy

List of the studies conducted for diseases and EDC by study design

	Total	Cohort	Nested CaCo	Retro. CaCo	Cross sectional	Eco-logical	For Japanese
Breast	72	8	14	38	6	6	0
Endometrium	2	0	0	2	0	0	0
Ovary	8	3	0	2	0	3	0
Prostate	24	10	3	6	0	5	0
Testis	19	7	0	9	0	3	0
Thyroid	6	3	0	0	0	3	0
hypospadias	8	2	0	6	0	0	0
cryptorchidism	13	1+1	0	11	0	0	0
Child develop.	39	35	0	1	2	1	1
endometriosis	6	0	0	4	2	0	0
Thyroid function	15	2+1	0	1	10	1	2
Sperm count	30	1	1	9	18	1	1
allergy	5	3	0	1	1	0	0

Points to consider 1

- Why are there many ecological studies in cancer but not in other diseases ?
 - Monitoring system for incidence and mortality in population differs among diseases
 - Cancer: incidence from cancer registry, mortality from vital statistics
 - Other diseases: very few diseases have disease registry, vital statistics is no use for nonfatal diseases

Points to consider 2

- Why are cohort studies common ?
 - Exposure of interest is mainly DES or occupational exposure such as pesticide users
 - Retrospective definition of cohort
 - Retrospective definition of exposure, no biological measurements
 - “historical cohort” study
- Why can nested case-control study (=prospective study using stored biological specimen) be done only for cancer ?
 - Use of already existing multipurpose cohort
 - Stored sample, other exposures, and endpoint ascertainment system can be used
 - Example: Nurses’ Health Study

Difficulties in conducting cohort study in Japan

An example from JPHC Study

Cohort I

All the residents
with age 50-69 at 1990

Ninohe, Iwa
(12,291)


Yokote, Aki
(15,782)

Saku, Nagara
(12,219)

Katsushika, Tokyo
(7,097)

Chubu, Okina
(14,206)

Map of JPHC Study area



Cohort II

All the residents with
Age 40-69 at 993

Kashiwazaki, Niigata
(3,571)

Mito, Ibaraki
(21,467)

Suita, Osaka
(16,437)

Chuo-higashi, Kochi
(8,606)

Kamigoto, Nagasaki
(14,624)

Miyako, Okinawa
(14,109)

Baseline survey

- questionnaire
- blood, health check-up

5 year follow-up survey

- questionnaire
- blood, health check-up

10 year follow-up survey

- questionnaire

* Public Health Center,
Prefecture (# of
subjects)

Cohort I

1990

1995

2000

Cohort II

1993

1998

2003

Self-administered questionnaire

- JPHC Study, **baseline survey** -

- 14 pages color-printed questionnaire
(Partly modified for Cohort II)
 - Past medical/Family history
 - Smoking and drinking
 - Physical activity
 - Stress and social support
 - Residential / Occupational history
 - **Chemical and other environmental exposure**
 - Personality
 - Reproductive history
 - Diet
 - 44 or 46 food item FFQ
 - 4 or 5 frequency categories
 - Some with portion size
- Validation study was done for ~500 subjects

Cohort I (FFQ 44 items)

3. あなたは、どの位の頻度で食べますか？

ほとんど食べない 週1-2回 週3-4回 ほとんど毎日

ほとんど食べない 週1-2回 週3-4回 ほとんど毎日

4. 既往の病歴について、いずれかの番号の□をつけて下さい。

病名	過去	現在	無い
「こってり」とした料理は？	1	2	3
辛い料理、辛い料理は？	1	2	3
塩辛い料理、辛い料理は？	1	2	3
辛い料理、辛い料理は？	1	2	3
辛い料理、辛い料理は？	1	2	3
辛い料理、辛い料理は？	1	2	3

5. 最も多く受ける料理の調理方法について、1つだけ□をつけて下さい。

	煮る	蒸す	焼く	揚げたて	炒める	その他
肉類は？	1	2	3	4	5	6
魚介類は？	1	2	3	4	5	6
野菜類は？	1	2	3	4	5	6

6. 住まいや職場など過去に用いた料理を多く見る部屋はありますか？

ほとんど食べない 週1-2回 週3-4回 ほとんど毎日

7. 働き先のこたげな条件を覚えないようにしていますか？

はい いいえ

Cohort II (FFQ 46 items)

4. 質問書をご覧になって記入して下さい。お食事の食品について1週間(平日)の食生活の様子を、質問書中の食品の欄に記入して下さい。記入の際は、食品の種類や調理方法によって異なる場合も、その食品の種類を記入して下さい。

食品	頻度	分量	備考
肉類			
魚介類			
野菜類			
果物			
豆類			
穀類			
その他			

5. 1週間(平日)の食生活の様子を、質問書中の食品の欄に記入して下さい。記入の際は、食品の種類や調理方法によって異なる場合も、その食品の種類を記入して下さい。

食品	頻度	分量	備考
肉類			
魚介類			
野菜類			
果物			
豆類			
穀類			
その他			

Collection of blood samples

- JPHC Study, **baseline survey** -

- 10 ml peripheral blood in heparinized tube
- centrifuged within 12 hours
- 3 tubes (1 ml) for plasma
- 1 tube (1 ml) for buffy layer
- stored at -80



Conduct of questionnaire survey

- >80% participation rate for 140,000 subjects
 - Questionnaire delivered to house and collected several days later
 - >1,000 coordinators
- ~35% Participation rate for Blood sampling
 - Collected at the health check-up examination
 - Informed consent and voluntarism in Japanese
- Costly

Events collected during the follow-up

- Mortality:** Population registry at local municipalities
Death certificates at public health center
- Migration:** Population registry at local municipalities
- Incidence** (cancer, cerebrovascular disease and ischemic heart disease): Medical records at local hospitals
Population-based registry (Prefecture-wide) for cancer

Registration Form
for
Cancer, CVD, IHD

この登録票は厚生省コホート研究班における統計作業の目的にのみ使用されます。
転写の際は、転写ミスがないようにしてください。

厚生省コホート研究班
がん登録票

ID番号: _____ 登録者名: _____

凡例
氏名: _____ (姓) 性別: _____ 生年月日: _____ (年 月 日) 年齢: _____ 性別: _____

発症年月日: _____ (平成 年 月 日)
診断年月日: _____ (平成 年 月 日)

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

病名 (原病) _____ 腫瘍コード: _____
病名 (転移) _____ 腫瘍コード: _____

備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)
備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)

登録票記入日 平成 ____ 年 ____ 月 ____ 日 施設名: _____
記入者名: _____

この登録票は厚生省コホート研究班における統計作業の目的にのみ使用されます。
転写の際は、転写ミスがないようにしてください。

厚生省コホート研究班
脳卒中登録票

ID番号: _____ 登録者名: _____

凡例
氏名: _____ (姓) 性別: _____ 生年月日: _____ (年 月 日) 年齢: _____

発症年月日: _____ (平成 年 月 日)
診断年月日: _____ (平成 年 月 日)

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

病名 (原病) _____ 腫瘍コード: _____
病名 (転移) _____ 腫瘍コード: _____

備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)
備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)

登録票記入日 平成 ____ 年 ____ 月 ____ 日 施設名: _____
記入者名: _____

この登録票は厚生省コホート研究班における統計作業の目的にのみ使用されます。
転写の際は、転写ミスがないようにしてください。

厚生省コホート研究班
心筋梗塞・急性死登録票

ID番号: _____ 登録者名: _____

凡例
氏名: _____ (姓) 性別: _____ 生年月日: _____ (年 月 日) 年齢: _____

発症年月日: _____ (平成 年 月 日)
診断年月日: _____ (平成 年 月 日)

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

診断方法: 1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡
6. その他

病名 (原病) _____ 腫瘍コード: _____
病名 (転移) _____ 腫瘍コード: _____

備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)
備考 (1. 病歴問診 2. 画像診断 3. 血液検査 4. 胸腔造影 5. アンダード顕微鏡)

登録票記入日 平成 ____ 年 ____ 月 ____ 日 施設名: _____
記入者名: _____

Difficulties in follow-up ascertainment of diseases

- No good existing source of monitoring diseases
 - Only cancer registry but quality is not so good
- Voluntary report from hospitals
 - No incentives of hospital doctors
- Active collection by hospital visit
 - Many hospitals should be covered in study areas (esp. if Tokyo, Osaka, etc.)
- Self-report is not reliable
 - Poor: cancer, cardiovascular diseases
 - Moderate: Diabetes Mellitus
 - Health check-up exam
 - Good: Cataract

Difficulties in follow-up

- Many resources are needed
 - money, organization, people
- Poor Social understanding for research
 - Privacy protection regulations and informed consent
 - No unique ID such as social security number

Required events and sample size for 10 year follow-up in crude analysis

Rate in the 1st exposure quintile (1/100,000)		Relative Risks in the 5th quintile		
		1.5	2.0	3.0
1	n	3,979,000	1,225,000	434,000
	# of death	497	184	87
5	n	796,000	245,000	87,000
	# of death	497	184	87
10	n	398,000	123,000	43,000
	# of death	497	184	87
20	n	199,000	61,000	22,000
	# of death	497	184	87
30	n	133,000	41,000	14,000
	# of death	497	184	87
100	n	40,000	12,000	4,000
	# of death	497	184	87

2 sided alpha=0.05 and power=80%

Why few studies conducted in Japan?

- Poor availability of disease monitoring system
- Costly
- Few existing cohort with sufficient cases and biological specimen

Other available designs ?

List of the studies conducted for disease and EDC by study design


	Total	Cohort	Nested CaCo	Retro. CaCo	Cross sectional	Eco-logical	For Japanese
Breast	72	8	14	38	6	6	0
Endometrium	2	0	0	2	0	0	0
Ovary	8	3	0	2	0	3	0
Prostate	24	10	3	6	0	5	0
Testis	19	7	0	9	0	3	0
Thyroid	6	3	0	0	0	3	0
hypospadias	8	2	0	6	0	0	0
cryptorchidism	13	1+1	0	11	0	0	0
Child develop.	39	35	0	1	2	1	1
endometriosis	6	0	0	4	2	0	0
Thyroid function	15	2+1	0	1	10	1	2
Sperm count	30	1	1	9	18	1	1
allergy	5	3	0	1	1	0	0

Points to consider 3

- New study is necessary
 - To obtain sufficient biological materials
 - Prospective study takes cost and time
 - evidence level should be as high as possible
- Available design is retrospective case-control study

An example from Childhood leukemia Study

- Objective
 - To investigate the factors related to the incidence of childhood *LK*
- Study design
 - Population-based
 - retrospective case-control study
- Factors of interest
 - Life-style factors and family history
 - Electric Magnetic Field exposure
 - **Chemical and other environmental exposure**





Biggest difficulty: Low participation rate

- 312 cases and 603 controls from all over Japan
 - Originally 500 cases and 3 matched controls were planned
- Case participation rate: 50%
 - Case referrals from childhood leukemia group
 - Accessibility to cases was difficult
 - ~80% participation once referred
- Control participation rate: 30%
 - 10 Control candidates were selected from the resident registration system
 - Handwriting from the list
 - Participation request by Mail
 - ~30% is typical for mail survey
 - 30% cannot rule out selection bias
 - Validation study to prove no selection bias

Retrospective Case-Control study

- Population-based
 - Better but difficult to sample control randomly from the population which case arises
 - Difficulty in identifying source population for cases
 - Difficulty in random sampling
 - List making, rejection to participate in the study
 - Costly to obtain measurements at home
 - **Not feasible in Japan**
- Hospital-based
 - More feasible but not a random sample from the population which case arises
 - No assurance of randomness
 - Risk of exposure is underestimated if disease of control subjects is associated with the exposure
 - *Feasible in Japan*

Feasible design for new EDC epi study

Historical cohort study		Retrospective case-control study
Drug use/occupational exposure in category	 Exposure 	Biological measurements but after diagnosis
Few information	Confounder	Questionnaire but after diagnosis
Same	Population which cases and controls occur	No assurance
Multiple if registry or data is available	Target Diseases	One
~1 year	Research Period	Several years
Several hundreds	# of cases needed	Several hundreds
># cases x 100	Number of subjects	# cases x 2-6
<\$ million	Cost	\$ several million
accuracy of exposure & confounder information	Quality depends on:	selection bias & confounder information

Summary of difficulty and proposal for conducting Prospective study

- **Historical cohort study**
 - Difficulty depends on collection of incidence data
 - Exposure information may be obtained if past exposure is identified retrospectively such as DES use or occupational exposure
- Nested case-control studies (w/biological specimen)
 - New study is very costly
 - Use of existing cohort studies is practical if it exists
- **Collaboration with other epidemiologists is critical**

Summary of difficulty and proposal for conducting retrospective study

- Case-control study
 - Population-based case-control studies
 - Impossible if the list of population is not available
 - Low participation rates does not assure no selection bias
 - Hospital-based case-control studies
 - *Most feasible design* but no assurance of no selection bias, i.e. comparability of cases and control
- Collaboration with clinicians is critical

Thank you for your attention!